TUSC2 emerges as a pivotal tumor suppressor, with its decreased expression commonly observed in various cancers, including lung cancer [37], malignant mesothelioma [38], soft-tissue sarcoma [39], high-grade human glioma [40], and thyroid cancer [41]. Here, TUSC2 is linked to central nervous system cancer.